Clinical trials: open to volunteers, in Croatia
Alzheimer Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Trial name
- NCT07011732
- Testing
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule
- Where
- 162 sites in United States, Argentina and 13 more
- Volunteers
- 426 people
- Sponsor
- Bristol-Myers Squibb
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT07218341
- Testing
- Pirtobrutinib, Idelalisib
- Where
- 50 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Inflammatory Bowel Diseases, Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's…
- Trial name
- GARNET (NCT06226883)
- Testing
- MORF-057
- Where
- 224 sites in United States, Australia and 26 more
- Volunteers
- 385 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Immune Thrombocytopenic Purpura (ITP)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06722235
- Testing
- Mezagitamab
- Where
- 124 sites in United States, Australia and 16 more
- Volunteers
- 171 people
- Sponsor
- Takeda
Atrial Fibrillation, Atrial Flutter
Anatomical Navigation for Guided Electrophysiology in AFL and AFib
The objective of the study is to collect data on the use of the VERAFEYE Anatomical Guidance System in adult patients indicated to undergo a catheter ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Atrial Arrhythmia
- Trial name
- ANGEL-AF (NCT07210151)
- Testing
- VERAFEYE Anatomic Guidance System
- Where
- 4 sites in Croatia, Czechia and 1 more
- Volunteers
- 50 people
- Sponsor
- LUMA Vision Ltd.
Atrial Fibrillation, Atrial Flutter
Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures
The objective of the study is to collect data on the usability and integration of the VERAFEYE Imaging and Guidance System in adult patients indicated to undergo a standard of care catheter-based ablation procedure for the…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Atrial Arrhythmia
- Trial name
- INSiGHT (NCT07271238)
- Testing
- VERAFEYE Imaging and Guidance System
- Where
- Croatia
- Volunteers
- 50 people
- Sponsor
- LUMA Vision Ltd.
Agitation Associated With Alzheimer's Dementia
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.
- Trial name
- NCT06651567
- Testing
- ITI-1284
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 320 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Psychotic Disorders, Alzheimer Disease
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in…
- Trial name
- NCT06540833
- Testing
- ITI-1284
- Where
- 71 sites in United States, Bulgaria and 8 more
- Volunteers
- 370 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Carcinoma, Squamous Cell
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in…
- Trial name
- NCT04892173
- Testing
- JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
- Where
- 196 sites in United States, Austria and 25 more
- Volunteers
- 500 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Trial name
- NCT07067463
- Testing
- Orelabrutinib
- Where
- 83 sites in United States, Australia and 15 more
- Volunteers
- 705 people
- Sponsor
- Zenas BioPharma (USA), LLC
Severe Infection
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
Ceftazidime/avibactam (CZA) is an essential treatment option for managing infections caused by multidrug-resistant (MDR) gram-negative (G-) bacteria, including Klebsiella pneumoniae OXA-48 and carbapenem-resistant Pseudomonas…
- Trial name
- ZAVICONT (NCT06811727)
- Testing
- Continuos ceftazidime/avibactam infusion, Intermitent dosing as per SMPC
- Where
- Croatia
- Volunteers
- 140 people
- Sponsor
- Ivan Šitum, MD
Head and Neck Cancer
Airway Ultrasound in Oncologic Maxillofacial Patients
This prospective observational cohort study will evaluate ultrasound-based airway measurements in adult patients with oncologic maxillofacial disease undergoing surgery under general anesthesia.
- Trial name
- NCT07910149
- Where
- 2 sites in Croatia
- Volunteers
- 30 people
- Sponsor
- University Hospital Dubrava
Focal Epilepsy, Tonic-Clonic Seizures
An Open-label Study of XEN1101 in Epilepsy
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of…
- Trial name
- X-TOLE4 (NCT05718817)
- Testing
- XEN1101
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 880 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depressive Disorder
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Trial name
- NCT06966401
- Testing
- NBI-1065845
- Where
- 120 sites in United States, Australia and 21 more
- Volunteers
- 850 people
- Sponsor
- Neurocrine Biosciences
Primary Generalized Tonic-Clonic Seizures
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic…
- Trial name
- X-ACKT (NCT05667142)
- Testing
- XEN1101
- Where
- 141 sites in United States, Argentina and 18 more
- Volunteers
- 160 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- NCT05716100
- Testing
- XEN1101
- Where
- 103 sites in United States, Argentina and 19 more
- Volunteers
- 360 people
- Sponsor
- Xenon Pharmaceuticals Inc.